EGFR and neoplasm: In LG1179 (Kras G13R; Kras mutants are typically non-responsive to EGFR TKIs), one 1.5 mg/kg dose of RN765C resulted in sustained tumor regression while multiple doses of carboplatin were ineffective and gemcitabine only moderately slowed down tumor growth (Figure 5B).